Cre-ERT2 recombinase systems
GPTKB entity
Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
genetic tool
|
| gptkbp:activatedBy |
gptkb:tamoxifen
|
| gptkbp:advantage |
low background activity
tight control of recombination timing |
| gptkbp:alternativeTo |
Cre-ERT recombinase systems
Cre-PR recombinase systems |
| gptkbp:component |
gptkb:Cre_recombinase
ERT2 mutant estrogen receptor ligand-binding domain |
| gptkbp:developedBy |
genetic engineering researchers
|
| gptkbp:enables |
spatial control of gene recombination
temporal control of gene recombination |
| gptkbp:expressedIn |
tissue-specific promoters
ubiquitous promoters |
| gptkbp:firstDescribed |
1999
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cre-ERT2 recombinase systems
|
| gptkbp:limitation |
tamoxifen toxicity at high doses
variable recombination efficiency |
| gptkbp:mechanismOfAction |
tamoxifen binding releases Cre from cytoplasm to nucleus
|
| gptkbp:regulates |
tamoxifen administration schedule
|
| gptkbp:relatedTo |
Cre-LoxP system
inducible genetic systems |
| gptkbp:species |
gptkb:mouse
gptkb:zebrafish right |
| gptkbp:usedFor |
inducible gene recombination
|
| gptkbp:usedIn |
cancer research
developmental biology neuroscience conditional knockout experiments fate mapping lineage tracing |
| gptkbp:bfsParent |
gptkb:4-hydroxytamoxifen
|
| gptkbp:bfsLayer |
7
|